A leading UK University was developing an innovative technology to permit the creation of surface-immobilized functional RNAs in a microarray format, by transcription and ‘printing’ from corresponding cDNA microarrays. The technology had provided promising preliminary results, however, it needed direction in selecting the best commercial applications. Alacrita was therefore asked to explore the most viable applications for the RNA array and to advise on the most valuable path to commercialization.
Our consultants met with the Principal Investigator to learn more about the technology and development to date. With this information a commercialization roadmap was created exploring the characterization of the identified commercial opportunities, including transcription profiling, monitoring of transcription, monitoring translation etc, in terms of:
- Market opportunity
- Competitive environment, including alternative products/technologies
- The “fit” of the RNA array technology to address the opportunity
- Potential routes to market
- Identification of strongest prospects for potential partners/collaborators
- Project status and further work required before commercial engagement
After exploring all proposed applications, Alacrita noted that all would require further development work to demonstrate utility, requiring further translational grant funding or partnering support. Once adequate proof of concept data had been collected Alacrita advised the University to seek commercialization with a large reagents/tools company.
Strategy & Commercialization
Our team of expert pharmaceutical business consultants provides deep knowledge in critical areas such as company and portfolio strategies, fundraising pitch materials, platform or program opportunity-feasibility assessments, new product planning, value-based pricing and market access, and product launch preparations.Back